DFDV holds 2.33 million SOL against $215 million of liabilities. Strip the debt out and the equity is worth roughly $1.54 a share. It trades at $5.28 after doubling in seventeen sessions on a treasury press release. The company has a $199 million ATM sitting unused and $4.3 million of cash. We are short, target $2.30.

Read the complete report at Shortfinder.com (paid subscription required).

Read the full text of the report at Shortfinder.com (free registration required).

Read the full text of the report at Shortfinder.com (free registration required).

The full text of this report is available at Shortfinder.com (free registration required).

The full text of this report is available at Shortfinder.com (paid subscription required).

The full text of this report is available at shortfinder.com (free registration required).

The full text of this report is available at shortfinder.com (paid subscription required).

Executive Summary

Altimmune is a 59-employee clinical-stage biotech with zero commercial revenue, a single drug candidate (pemvidutide) that missed its primary fibrosis endpoint in Phase 2b, and a pattern of serial dilution that has inflated the share count 174% in eighteen months. The company’s stock has fallen 61% from its June 2025 peak of $7.71, yet the remaining overhang from the April 2026 underwritten offering — 75 million warrants exercisable at $3.00, plus unsold shares — threatens further decline. Shortfinder’s machine-learning models assign ALT a persistent top-5% risk ranking, driven by dilution frequency, high-risk institutional holders, and negative price momentum across every measured horizon.

The thesis rests on five pillars:

1. Relentless dilution — three capital raises totaling $510M in six months (Nov 2025–Apr 2026), with 200M shares outstanding having doubled from a year prior

2. Weak clinical position — pemvidutide showed MASH resolution but failed its fibrosis endpoint, the metric the FDA and market weight most heavily

3. High-risk institutional capital — two of the five largest holders (RA Capital, Deep Track Capital) appear in Shortfinder’s Toxic Investor registry; all five exhibit high post-investment decline patterns

4. Massive warrant overhang — 75M warrants with a strike price of $3.00 create a ceiling at or near the current price; any rally above $3.00 will drive warrant exercises and immediate selling

5. Debt covenants constrain flexibility — the Hercules term loan ($34.5M) adds fixed servicing costs and likely includes minimum cash covenants that could force future raises

The full text of this report is available at shortfinder.com (free registration required).

The full text of this report is available on Shortfinder.com (paid subscription required).

The full text of this report is available at shortfinder.com (free registration required).

The full text of this report is available at Shortfinder.com (Professional tier subscription required).

This report is available to free subscribers at shortfinder.com.

This report is available to paid subscribers at shortfinder.com.

The full text of this report is available exclusively at shortfinder.com (free registration required).

The full text of this report is available exclusively at shortfinder.com (free registration required).

The full text of this report is available exclusively at shortfinder.com (free registration required).

The full text of this report is available exclusively at shortfinder.com (free registration required).

Go to shortfinder.com

The full text of this report is available at Shortfinder.com (Professional tier subscription required).

The full text of this report is available at Shortfinder.com (Professional tier subscription required).